Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Intramuscular TAK-816 in Healthy Infants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Japanese infants.~2. Male or female infants aged 2-6 months (≥2 and \<7 months) at the time of the first dose of investigational product (excluding hospitalized infants).~3. Infants whose parents or legal guardians have agreed to cooperate with the investigator during the study period.~4. The legal guardian signed and dated a written, informed consent form prior to the initiation of any study procedures.~Exclusion Criteria:~1. Any serious acute illness.~2. Any underlying cardiovascular, renal, hepatic, or hematologic disease, and/or developmental disorder.~3. History of possible Haemophilus influenzae type b (Hib) infection.~4. Previously diagnosed immunodeficiency.~5. Documented history of anaphylaxis to any ingredients of the investigational product (e.g., diphtheria toxoid).~6. A history of convulsions.~7. Previous administration of another Hib vaccine.~8. Treatment with any live vaccine during the 27 days before the first dose of TAK-816 or with any inactivated vaccine during the 6 days before dosing.~9. Prior participation in any clinical study or post-marketing clinical study.~10. Previously receipt of blood transfusions, gamma globulin preparations (except monoclonal antibody products not containing any components of Hib as antigens), systemic immunosuppressive therapy, or systemic corticosteroids, or a plan to receive any of these products during the study period.~11. Presence of thrombocytopenia or coagulopathy.~12. Children considered ineligible for the study for other reasons by the investigator or subinvestigator.

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 6 Months
- Healthy Volunteers: t

Study Arms:
- TAK-816 0.5 mL (Type: EXPERIMENTAL): Primary immunization: TAK-816 0.5 mL, intramuscular injection, once on Day 1 and every 28 days for 2 intervals (Days 29 and 57). Booster immunization: TAK-816 0.5 mL, intramuscular injection, once, 52 weeks after the third dose of primary immunization.

Based on this trial design, predict the completion outcome and termination type (if applicable).